Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
Daniel R. Principe, Patrick W. Underwood, Murray Korc, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 155

Showing 1-25 of 155 citing articles:

Clinical trial design in the era of precision medicine
Elena Fountzilas, Apostolia M. Tsimberidou, Henry Hiep Vo, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 160
Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
Hayden Pearce, Wayne Croft, Samantha M. Nicol, et al.
Cancer Immunology Research (2023) Vol. 11, Iss. 4, pp. 435-449
Open Access | Times Cited: 36
FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer
Marta Canel, Aleksandra Dominika Sławińska, David W. Lonergan, et al.
Gut (2023) Vol. 73, Iss. 1, pp. 131-155
Open Access | Times Cited: 29
Exosomes define a local and systemic communication network in healthy pancreas and pancreatic ductal adenocarcinoma
Bárbara Adem, Nuno Bastos, Carolina F. Ruivo, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer
Zainab Hussain, Thomas Bertran, Pascal Finetti, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
TGFβ Signaling in the Pancreatic Tumor Microenvironment
Daniel R. Principe, Kaytlin E. Timbers, Luke G. Atia, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5086-5086
Open Access | Times Cited: 50
Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies
Alaa Y. Bazeed, Candace M. Day, Sanjay Garg
Cancers (2022) Vol. 14, Iss. 17, pp. 4257-4257
Open Access | Times Cited: 33
Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer
Daniel R. Principe, Alexandre F. Aissa, Sandeep Kumar, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 18
Open Access | Times Cited: 28
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
Andrew H. Ko, Kyu‐pyo Kim, Jens T. Siveke, et al.
The Oncologist (2023) Vol. 28, Iss. 6, pp. 553-e472
Open Access | Times Cited: 22
High hypoxia status in pancreatic cancer is associated with multiple hallmarks of an immunosuppressive tumor microenvironment
Hassan Sadozai, Animesh Acharjee, Hateem Zafar Kayani, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
A Current Synopsis of the Emerging Role of Extracellular Vesicles and Micro-RNAs in Pancreatic Cancer: A Forward-Looking Plan for Diagnosis and Treatment
Eleni-Myrto Trifylli, Anastasios G. Kriebardis, Evangelos Koustas, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3406-3406
Open Access | Times Cited: 7
Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Pingshan Zhong, Kohei Nakata, Koki Oyama, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 7
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors
Changhoon Yoo, Ángela Lamarca, Hye Jin Choi, et al.
Future Oncology (2024) Vol. 20, Iss. 16, pp. 1069-1077
Open Access | Times Cited: 6
Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition
Ranjeet Singh, Prateek Srivastava, Partha Pratim Manna
Medical Oncology (2024) Vol. 41, Iss. 2
Closed Access | Times Cited: 6
Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer
Daniel R. Principe, Patrick W. Underwood, Sandeep Kumar, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 24
Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma
Ioana Plesca, Iva Benešová, Carolin Beer, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1216-1216
Open Access | Times Cited: 24
Antibody drug conjugates: hitting the mark in pancreatic cancer?
Nicole L. Wittwer, Michael P. Brown, Vasilios Liapis, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 16
The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer
Imke Stouten, Nadine van Montfoort, Lukas J.A.C. Hawinkels
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8707-8707
Open Access | Times Cited: 13
Impact of exosome therapy on pancreatic cancer and its progression
Mohamed El‐Tanani, Hamdi Nsairat, Ismail Matalka, et al.
Medical Oncology (2023) Vol. 40, Iss. 8
Open Access | Times Cited: 13
Outcomes in intraductal papillary mucinous neoplasm‐derived pancreatic cancer differ from PanIN‐derived pancreatic cancer
Joseph R. Habib, Ingmar F. Rompen, Ammar A. Javed, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 11, pp. 2360-2366
Open Access | Times Cited: 5
Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition
Daniel R. Principe
Cancers (2022) Vol. 14, Iss. 4, pp. 897-897
Open Access | Times Cited: 22
Novel Liposomal Formulation of Baicalein for the Treatment of Pancreatic Ductal Adenocarcinoma: Design, Characterization, and Evaluation
Adam Markowski, Magdalena Zaremba-Czogalla, Anna Jaromin, et al.
Pharmaceutics (2023) Vol. 15, Iss. 1, pp. 179-179
Open Access | Times Cited: 12
Enhancing chemotherapy for pancreatic cancer through efficient and sustained tumor microenvironment remodeling with a fibroblast-targeted nanosystem
Xinyuan Zhou, Pan Zhang, Nan Liu, et al.
Journal of Controlled Release (2023) Vol. 361, pp. 161-177
Closed Access | Times Cited: 11
Minimally invasive pancreaticoduodenectomy: A favorable approach for frail patients with pancreatic cancer
Emile Farah, Amr I. Al Abbas, Andres A. Abreu, et al.
Surgery (2024) Vol. 175, Iss. 4, pp. 1168-1175
Closed Access | Times Cited: 4
Progress of single-cell RNA sequencing combined with spatial transcriptomics in tumour microenvironment and treatment of pancreatic cancer
Jie Zhu, Ke Zhang, Chen Yuan, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top